DK3068428T3 - Annexin-ii-variant-sammensætninger og fremgangsmåder - Google Patents

Annexin-ii-variant-sammensætninger og fremgangsmåder Download PDF

Info

Publication number: DK3068428T3
Authority: DK; Denmark
Prior art keywords: annexin; methods; variant compositions; variant; compositions
Prior art date: 2013-11-13

Application number

DK14812331.8T

Other languages

English (en)

Inventor

John R Ohlfest

Michael R Olin

Original Assignee

Univ Minnesota

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-13

Filing date

2014-11-13

Publication date

2022-10-17

2014-11-13 Application filed by Univ Minnesota filed Critical Univ Minnesota

2022-10-17 Application granted granted Critical

2022-10-17 Publication of DK3068428T3 publication Critical patent/DK3068428T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Marine Sciences & Fisheries (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK14812331.8T 2013-11-13 2014-11-13 Annexin-ii-variant-sammensætninger og fremgangsmåder DK3068428T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361903628P	2013-11-13	2013-11-13
PCT/US2014/065390 WO2015073632A1 (en)	2013-11-13	2014-11-13	Annexin ii variant compositions and methods

Publications (1)

Publication Number	Publication Date
DK3068428T3 true DK3068428T3 (da)	2022-10-17

Family

ID=52101577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14812331.8T DK3068428T3 (da)	2013-11-13	2014-11-13	Annexin-ii-variant-sammensætninger og fremgangsmåder

Country Status (9)

Country	Link
US (1)	US10206986B2 (da)
EP (1)	EP3068428B1 (da)
AU (1)	AU2014348645B2 (da)
CA (1)	CA2930567C (da)
DK (1)	DK3068428T3 (da)
ES (1)	ES2928331T3 (da)
HU (1)	HUE060293T2 (da)
PL (1)	PL3068428T3 (da)
WO (1)	WO2015073632A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180133327A1 (en) *	2015-03-16	2018-05-17	Amal Therapeutics Sa	Cell Penetrating Peptides and Complexes Comprising the Same
RU2769314C1 (ru)	2016-03-16	2022-03-30	Амаль Терапьютикс Са	Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
SI3468621T1 (sl) *	2016-06-10	2023-01-31	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Jedrna domena aneksinov in uporabe le-teh pri odmerjanju antigena in cepljenju
HUE067838T2 (hu) *	2016-09-21	2024-11-28	Amal Therapeutics Sa	Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7262167B2 (en)	1995-11-06	2007-08-28	Exibona Ltd.	Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US6645465B2 (en)	1999-08-06	2003-11-11	Michigan, University Of The Regents	Annexin proteins and autoantibodies as serum markers for cancer
DE60124927T2 (de) *	2000-09-01	2007-09-20	Philadelphia Health And Education Corp.	Verfahren und zusammensetzungen zur inhibition der angiogenese
DE10225144A1 (de)	2002-05-29	2003-12-18	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7695725B2 (en)	2003-02-06	2010-04-13	Aduro Biotech	Modified free-living microbes, vaccine compositions and methods of use thereof
EP3115063A3 (en)	2008-12-03	2017-04-19	The John Hopkins University	Galectin-3 and annexin-a2 as immunological target
KR101121198B1 (ko)	2009-05-20	2012-03-23	(주)노바셀테크놀로지	태반에서 추출된 펩타이드 혼합물, 그의 제조 방법 및 용도
WO2012048190A1 (en)	2010-10-08	2012-04-12	Regents Of The University Of Minnesota	Annexin ii compositions and methods

2014
- 2014-11-13 HU HUE14812331A patent/HUE060293T2/hu unknown
- 2014-11-13 EP EP14812331.8A patent/EP3068428B1/en active Active
- 2014-11-13 PL PL14812331.8T patent/PL3068428T3/pl unknown
- 2014-11-13 US US15/036,115 patent/US10206986B2/en active Active
- 2014-11-13 ES ES14812331T patent/ES2928331T3/es active Active
- 2014-11-13 DK DK14812331.8T patent/DK3068428T3/da active
- 2014-11-13 CA CA2930567A patent/CA2930567C/en active Active
- 2014-11-13 WO PCT/US2014/065390 patent/WO2015073632A1/en not_active Ceased
- 2014-11-13 AU AU2014348645A patent/AU2014348645B2/en active Active

Also Published As

Publication number	Publication date
WO2015073632A1 (en)	2015-05-21
US20160279212A1 (en)	2016-09-29
CA2930567C (en)	2023-09-26
AU2014348645B2 (en)	2019-01-24
ES2928331T3 (es)	2022-11-17
HUE060293T2 (hu)	2023-02-28
EP3068428A1 (en)	2016-09-21
CA2930567A1 (en)	2015-05-21
EP3068428B1 (en)	2022-08-17
US10206986B2 (en)	2019-02-19
PL3068428T3 (pl)	2023-03-13
AU2014348645A1 (en)	2016-06-02

Publication	Publication Date	Title
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
BR112015028459A2 (pt)	2017-09-26	composições e comestíveis
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK2968443T3 (da)	2021-12-06	Hepcidinanaloger og anvendelser deraf
EP2953474A4 (en)	2016-12-28	COMPOSITIONS AND METHODS
DK3381917T3 (da)	2021-10-18	Imidazopyridinforbindelser og anvendelser deraf
EP2889350A4 (en)	2016-05-18	ADHESIVE COMPOSITION
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
EP2989885A4 (en)	2016-12-14	HARVESTER
DK2986722T3 (da)	2019-05-13	Manipulerede phenylalaninammoniak-lyasepolypeptider
DK3065771T3 (da)	2019-06-11	Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3027750T3 (da)	2019-07-15	Biokatalytisk sammensætning
DK3058936T3 (da)	2019-05-13	Peptidsammensætning og anvendelser deraf
EP2970569A4 (en)	2016-07-27	PERSISTENT CARBENE AND COMPOSITIONS WITH IT
DK3052081T3 (da)	2021-01-18	Pastil
DK3060200T3 (da)	2021-07-12	Tyrosinderivater og sammensætninger dermed
DK3060460T3 (da)	2021-04-19	Saddel
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf
EP2972725A4 (en)	2016-12-07	SURVIVOR FACES
DK3027598T3 (da)	2017-05-22	Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da)	2021-03-22	Bindestrimler